Innovent Biologics Doses First Patient in Phase 3 Tigulixostat Study – Next‑Gen Xanthine Oxidase Inhibitor Targets Gout Market

Innovent Biologics, Inc. (HKG: 1801) announced that the first subject has been dosed in the Phase 3 clinical study of tigulixostat tablets (IBI128), a next‑generation non‑purine selective xanthine oxidase inhibitor (XOI), initiating a head‑to‑head comparison versus febuxostat for the treatment of hyperuricemia associated with gout – a potential superior treatment option for Chinese gout patients.

Clinical Milestone

Product Profile & Development History

• Molecule: Tigulixostat (IBI128) – next‑generation, non‑purine selective XOI
• Mechanism: Xanthine oxidase inhibition → reduced uric acid production
• Preclinical Validation: Unique mechanism of action confirmed
• Early‑Phase Evidence:
• Phase 1 & Phase 2: Significant uric acid‑lowering effects
• Safety Profile: Favorable tolerability
• Phase 3 Advancement: De‑risked by positive early‑phase data

Partnership Structure

Market Context & Competitive Positioning

Market Impact & Outlook

• Gout Therapeutics Market Dynamics: China gout market RMB8‑12 billion annually; dominated by generic allopurinol (70%+ share) and branded febuxostat (20‑25%); unmet need for safer, more effective XOIs to address febuxostat’s cardiovascular concerns and allopurinol’s suboptimal efficacy in rapid metabolizers.
• Tigulixostat Differentiation: “Next‑generation” positioning suggests improved cardiovascular safety profile vs. febuxostat and enhanced uric‑acid lowering potency vs. allopurinol; head‑to‑head Phase 3 design (vs. placebo‑controlled) demonstrates confidence in superiority claims.
• Innovent Portfolio Diversification: Tigulixostat adds small‑molecule metabolic disease asset to Innovent’s biologics‑dominant pipeline (PD‑1, bispecifics, ADCs); LG Chem partnership validates Innovent’s in‑licensing capabilities and China commercialization infrastructure.
• Clinical Development Timeline: Phase 3 enrollment 2026‑2027; primary completion 2028; NDA submission H2 2028; potential approval 2029‑2030; competitive race with domestic XOI candidates (Hengrui, CSPC reportedly in development).
• Commercial Strategy: Assuming non‑inferior/superior efficacy vs. febuxostat with improved cardiovascular safety, tigulixostat targets RMB1‑2 billion annual peak sales (2029‑2031) with 15‑20% China XOI market share; NRDL inclusion critical for volume access vs. generic allopurinol.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, efficacy expectations, and commercial projections for tigulixostat. Actual results may differ due to risks including Phase 3 head‑to‑head trial outcomes, competitive dynamics with established XOIs, and reimbursement policy developments.-Fineline Info & Tech